Glyset (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData, January 2012, Pages: 41

Glyset (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Glyset (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Glyset sales estimates for US, France, Germany, Spain and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Glyset including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Glyset including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2002-2020 for Glyset in the US, France, Germany,Spain and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Glyset, Type 2 Diabetes, Diabetes, miglitol, Seibule, Diastabol, Sales Forecasts, alpha-glucosidase inhibitor, Phase III, Phase 3, Pipeline, Competitors to Glyset - Lantus, Onglyza, Januvia, Janumet and Victoza, Pfizer, Sanofi-Aventis, Sanwa Kagaku Kenkyusho

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology and Risk Factors
2.3.1 Obesity
2.3.2 Sedentary Lifestyle
2.3.3 Family History and Genetics
2.3.4 Ethnicity
2.3.5 Old Age
2.4 Economic Impact of Diabetes
2.5 GlobalData Report Guidance
3 Type 2 Diabetes: Market Characterization
3.1 Type 2 Diabetes Market
3.2 Type 2 Diabetes Market Forecasts
3.3 Type 2 Diabetes Market: Drivers and Restraints
3.3.1 Drivers
3.3.2 Restraints
4 Classification of Diabetes
4.1 Types of Diabetes
4.1.1 Type 1 Diabetes
4.1.2 Type 2 Diabetes
4.1.3 Gestational Diabetes
4.2 Diabetes Complications
4.2.1 Cardiovascular Disease
4.2.2 Nephropathy
4.2.3 Neuropathy
4.2.4 Amputation
4.2.5 Retinopathy
5 Evolution of Anti-Diabetic Treatments
6 Medications
6.1 Insulin
6.2 Oral Medications
6.2.1 Sulfonylureas (SUR)
6.2.2 Biguanides (BGDs)
6.2.3 Alpha-Glucosidase Inhibitors (AGI)
6.2.4 Meglitinides
6.2.5 Thiazolidinediones (TZDs)
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
6.2.7 Oral Combination Therapy
6.3 Other Injectionable Medications
6.3.1 Pramlintide
6.3.2 Exenatide
6.4 Market Share as per Classes in Type 2 Diabetes
7 Glyset
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
7.3.1 Phase III Clinical Trials Evaluating Glyset in Non-Insulin Diabetes Mellitus Patients (NIDDM) Patients after Dietary Treatment Only.
7.3.2 Glyset in Non-Insulin Diabetes Mellitus Patients (NIDDM) Patients Receiving Sulfonylureas.
7.3.3 Glyset in Non Insulin Diabetes Mellitus Patients (NIDDM) Patients Receiving Metformin
7.4 Approval History of Glyset
7.5 Factors Affecting Sales of Glyset
7.5.1 Safety Profile
7.5.2 No Weight Gain
7.5.3 Patent Expiry of Miglitol
7.6 Drug Evaluation
7.6.1 Drug Risk Benefit Score
7.6.2 Intensity of Competition
7.7 Sales Estimates
7.7.1 Target Patient Pool for Glyset
7.7.2 Dosing
7.7.3 Market Penetration
7.7.4 Annual Cost of Therapy
7.7.5 Sales Projection of Glyset
8 Diabetes Market: Appendix
8.1 Market Definitions
8.2 List of Abberiviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of patients approved to take the drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables
Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
Table 8: Diabetes Drugs Evolution
Table 9: Results of Monotherapy study with Glyset
Table 10: Glyset Approval History
Table 11: Drug Risk Benefit Score
Table 12: Glyset, Type 2 Diabetes, Global, Sales Estimates ($m), 2002–2020
Table 13: Glyset, Type 2 Diabetes, The US, Sales Estimates ($m), 2002–2014
Table 14: Glyset, Type 2 Diabetes, France, Sales Estimates ($m), 2002–2012
Table 15: Glyset, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002–2012
Table 16: Glyset, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002–2013
Table 17: Glyset, Type 2 Diabetes, Japan, Sales Estimates ($m), 2006–2020

1.2 List of Figures
Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
Figure 3: Diabetes, World, Mortality, 2010
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020
Figure 6: Mechanism of Action of Sulfonylureas
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
Figure 9: Mechanism of Action of Thiazolidinediones
Figure 10: Mechanism of Action of DPP IV Inhibitors
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010
Figure 12: Glyset, Type 2 Diabetes, Global, Sales Estimates ($m), 2002–2020
Figure 13: Glyset, Type 2 Diabetes , The US, Sales Estimates ($m), 2002–2014
Figure 14: Glyset, Type 2 Diabetes, France, Sales Estimates ($m), 2002–2012
Figure 15: Glyset, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002–2012
Figure 16: Glyset, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002–2013
Figure 17: Glyset, Type 2 Diabetes, Japan, Sales Estimates ($m), 2006–2020
Figure 18: Patients Approved for the Drug

Customers who bought this item also bought

• Diabetes Diagnostics - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Hemoglobin A1c Monitoring - Global Strategic Business Report
• Blood Glucose Meters And Strips - Global Strategic Business Report
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Dental Supplies - Global Strategic Business Report
• Cord Blood Stem Cells – A Global Market Overview
• Molecular Diagnostics - Global Strategic Business Report
• Anesthesia Disposables - Global Strategic Business Report